Abstract:The Bcr-abl oncogene induces hematopoietic cell transformation and protects cells from apoptosis; however, the mechanisms whereby Bcr-abl blocks apoptosis are poorly defined. We examined whether the inhibitor of apoptosis protein (UP) family, in particular survivin, are regulated by Bcr-abl. Overexpression of Bcr-abl in Mo7e or BaF3 hematopoietic cells elevated survivin mRNA and protein concomitant with a 4-fold increase in survivin promoter activity. The region of the survivin promoter responding to Bcr-abl was narrowed down to a 116 bp fragment between nucleotides -1,194 and -1,078. The LAP family member LAP-like protein-2 was also upregulated by Bcr-abl. Disruption of Bcr-abl in Bcr-abl- transduced BaF3 cells by small interfering RNA resulted in 3- to 4-fold reduction in survivin protein confirming the link between Bcr-abl and survivin. Survivin disruption in Bcr-abl-transduced Mo7e cells, or in K562 cells that endogenously express Bcr-abl, by transfection with dominant-negative or antisense survivin constructs promoted apoptosis induced by the Bcr-abl tyrosine kinase inhibitor STI571, which was accompanied by caspase-dependent cleavage of Bcr-abl, mitochondrial membrane potential disruption, and enhanced mitochondrial cytochrome c release. Although ectopic survivin protected K562 cells from apoptosis induced by STI571, it did not protect cells from apoptosis induced either by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or the combination of TRAIL plus Hemin. Our results identify a new signal pathway downstream of Bcr-abl, in addition to the Bcl-2 family involved in the antiapoptotic effects of Bcr-abl, and suggest that anti-survivin therapy may have utility in patients with chronic myelogenous leukemia.

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

A Study on the Expression of Survivin Gene in Human Gastric Cancer

A Novel Anti-Apoptosis Gene: Re-expression of Survivin Messenger RNA as a Prognosis Marker in Non–Small-Cell Lung Cancers

Survivin (BIRC5): Implications in cancer therapy

Survivin as a Therapeutic Target for the Treatment of Human Cancer

A Novel Antiapoptosis Gene, Survivin, Bcl-2, P53 Expression in Cervical Carcinomas

Advances in the research of survivin and its anti-neoplastic application

Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma

Survivin Small Molecules Inhibitors: Recent Advances and Challenges

A key regulator of mitosis and apoptosis:Survivin,as a novel target for anticancer drug therapeutics

Expression of a Novel Apoptosis Inhibitor-Survivin in Colorectalcarcinoma

A Novel Autiapoptosis Gene,survivin Expression in Lung Squamous Carcinoma

Survivin Stable Knockdown by Sirna Inhibits Tumor Cell Growth and Angiogenesis in Breast and Cervical Cancers

Overexpression of Survivin Initiates Hematologic Malignancies in Vivo

The biology function of survivin on malignant tumor

Disruption Of The Inhibitor Of Apoptosis Protein Survivin Sensitizes Bcr-Abl-Positive Cells To Sti571-Induced Apoptosis

[Silencing of Survivin Gene in Jeko-1 Cell Line with Small Interfering RNA].

Expression of Survivin and Its Significance in Colorectal Cancer

Silencing of Survivin Expression Leads to Reduced Proliferation and Cell Cycle Arrest in Cancer Cells.

Survivin And Tumorigenesis: Molecular Mechanisms And Therapeutic Strategies

Effect on Apoptosis and Cell Cycle of Recombinant Double Negative Dominant Mutation Survivin (T34/117A) in Breast Cancer Cell B-Cap-37